SPARC to present updated clinical data of vodobatinib (SCO-088) at the 63rd ASH annual meeting

SPARC Licenses Development and Commercialization Rights of PDP-716 and SDN-037 to Visiox Pharma

SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target

SPARC to Provide Update on Clinical Programs and R&D Pipeline

SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of PDP-716 for the Treatment of Open Angle Glaucoma or Ocular Hypertension

SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of SDN-037 for the Treatment of Inflammation and Pain Associated with Ocular Surgery

SPARC Licenses Commercialization Rights of ElepsiaTM XR to Tripoint Therapeutics

SPARC to Provide Update on R&D Pipeline

SPARC enters into a worldwide license agreement for SCD-044 with Sun Pharma

SPARC to Provide Update on TaclantisTM NDA